Cancer immunotherapy: Benefit and harm?

In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a can...

Descripción completa

Detalles Bibliográficos
Autor principal: Characiejus, Dainius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376986/
https://www.ncbi.nlm.nih.gov/pubmed/22720253
http://dx.doi.org/10.4161/onci.1.2.18183
_version_ 1782235896782782464
author Characiejus, Dainius
author_facet Characiejus, Dainius
author_sort Characiejus, Dainius
collection PubMed
description In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded.
format Online
Article
Text
id pubmed-3376986
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33769862012-06-20 Cancer immunotherapy: Benefit and harm? Characiejus, Dainius Oncoimmunology Author's View In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded. Landes Bioscience 2012-03-01 /pmc/articles/PMC3376986/ /pubmed/22720253 http://dx.doi.org/10.4161/onci.1.2.18183 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Characiejus, Dainius
Cancer immunotherapy: Benefit and harm?
title Cancer immunotherapy: Benefit and harm?
title_full Cancer immunotherapy: Benefit and harm?
title_fullStr Cancer immunotherapy: Benefit and harm?
title_full_unstemmed Cancer immunotherapy: Benefit and harm?
title_short Cancer immunotherapy: Benefit and harm?
title_sort cancer immunotherapy: benefit and harm?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376986/
https://www.ncbi.nlm.nih.gov/pubmed/22720253
http://dx.doi.org/10.4161/onci.1.2.18183
work_keys_str_mv AT characiejusdainius cancerimmunotherapybenefitandharm

Ejemplares similares